![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LEF1 |
Gene summary for LEF1 |
![]() |
Gene information | Species | Human | Gene symbol | LEF1 | Gene ID | 51176 |
Gene name | lymphoid enhancer binding factor 1 | |
Gene Alias | LEF-1 | |
Cytomap | 4q25 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q659G9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51176 | LEF1 | LZE7T | Human | Esophagus | ESCC | 3.99e-05 | 1.79e-01 | 0.0667 |
51176 | LEF1 | P2T-E | Human | Esophagus | ESCC | 1.08e-21 | 4.94e-01 | 0.1177 |
51176 | LEF1 | P4T-E | Human | Esophagus | ESCC | 2.03e-18 | 4.82e-01 | 0.1323 |
51176 | LEF1 | P9T-E | Human | Esophagus | ESCC | 9.84e-07 | 2.32e-01 | 0.1131 |
51176 | LEF1 | P10T-E | Human | Esophagus | ESCC | 3.43e-16 | 4.18e-01 | 0.116 |
51176 | LEF1 | P12T-E | Human | Esophagus | ESCC | 4.80e-02 | 1.21e-01 | 0.1122 |
51176 | LEF1 | P15T-E | Human | Esophagus | ESCC | 5.02e-12 | 1.95e-01 | 0.1149 |
51176 | LEF1 | P16T-E | Human | Esophagus | ESCC | 3.63e-28 | 5.39e-01 | 0.1153 |
51176 | LEF1 | P23T-E | Human | Esophagus | ESCC | 6.85e-11 | 3.79e-01 | 0.108 |
51176 | LEF1 | P26T-E | Human | Esophagus | ESCC | 8.98e-20 | 3.52e-01 | 0.1276 |
51176 | LEF1 | P27T-E | Human | Esophagus | ESCC | 2.75e-29 | 6.33e-01 | 0.1055 |
51176 | LEF1 | P28T-E | Human | Esophagus | ESCC | 4.46e-04 | 1.53e-01 | 0.1149 |
51176 | LEF1 | P30T-E | Human | Esophagus | ESCC | 6.92e-04 | 2.79e-01 | 0.137 |
51176 | LEF1 | P32T-E | Human | Esophagus | ESCC | 1.89e-07 | 1.88e-01 | 0.1666 |
51176 | LEF1 | P39T-E | Human | Esophagus | ESCC | 2.79e-04 | 1.50e-01 | 0.0894 |
51176 | LEF1 | P42T-E | Human | Esophagus | ESCC | 1.78e-14 | 3.63e-01 | 0.1175 |
51176 | LEF1 | P48T-E | Human | Esophagus | ESCC | 4.05e-03 | 2.09e-01 | 0.0959 |
51176 | LEF1 | P52T-E | Human | Esophagus | ESCC | 1.57e-07 | 4.37e-01 | 0.1555 |
51176 | LEF1 | P54T-E | Human | Esophagus | ESCC | 5.94e-05 | 1.71e-01 | 0.0975 |
51176 | LEF1 | P56T-E | Human | Esophagus | ESCC | 5.36e-07 | 1.05e+00 | 0.1613 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
GO:006066914 | Esophagus | ESCC | embryonic placenta morphogenesis | 20/8552 | 26/18723 | 1.19e-03 | 5.88e-03 | 20 |
GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
GO:00101711 | Esophagus | ESCC | body morphogenesis | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
GO:0045637111 | Esophagus | ESCC | regulation of myeloid cell differentiation | 118/8552 | 210/18723 | 1.35e-03 | 6.43e-03 | 118 |
GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
GO:00603253 | Esophagus | ESCC | face morphogenesis | 21/8552 | 28/18723 | 1.57e-03 | 7.33e-03 | 21 |
GO:003582114 | Esophagus | ESCC | modulation of process of other organism | 64/8552 | 106/18723 | 1.61e-03 | 7.50e-03 | 64 |
GO:190210510 | Esophagus | ESCC | regulation of leukocyte differentiation | 152/8552 | 279/18723 | 1.82e-03 | 8.35e-03 | 152 |
GO:00487367 | Esophagus | ESCC | appendage development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
GO:00601737 | Esophagus | ESCC | limb development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
GO:00607119 | Esophagus | ESCC | labyrinthine layer development | 30/8552 | 44/18723 | 2.14e-03 | 9.54e-03 | 30 |
GO:005170214 | Esophagus | ESCC | biological process involved in interaction with symbiont | 57/8552 | 94/18723 | 2.46e-03 | 1.07e-02 | 57 |
GO:006071310 | Esophagus | ESCC | labyrinthine layer morphogenesis | 17/8552 | 22/18723 | 2.60e-03 | 1.11e-02 | 17 |
GO:00604856 | Esophagus | ESCC | mesenchyme development | 156/8552 | 291/18723 | 3.76e-03 | 1.53e-02 | 156 |
GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
GO:000276311 | Esophagus | ESCC | positive regulation of myeloid leukocyte differentiation | 37/8552 | 58/18723 | 4.12e-03 | 1.64e-02 | 37 |
GO:00456213 | Esophagus | ESCC | positive regulation of lymphocyte differentiation | 61/8552 | 104/18723 | 5.22e-03 | 1.97e-02 | 61 |
GO:00215436 | Esophagus | ESCC | pallium development | 94/8552 | 169/18723 | 5.79e-03 | 2.14e-02 | 94 |
GO:000276115 | Esophagus | ESCC | regulation of myeloid leukocyte differentiation | 69/8552 | 120/18723 | 6.00e-03 | 2.21e-02 | 69 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0521628 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa0521320 | Esophagus | ESCC | Endometrial cancer | 45/4205 | 58/8465 | 1.14e-05 | 5.98e-05 | 3.06e-05 | 45 |
hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa052215 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05210110 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa0516738 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0521517 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0521638 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa05213110 | Esophagus | ESCC | Endometrial cancer | 45/4205 | 58/8465 | 1.14e-05 | 5.98e-05 | 3.06e-05 | 45 |
hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0522113 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 5 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LEF1 | SNV | Missense_Mutation | c.194C>T | p.Pro65Leu | p.P65L | Q9UJU2 | protein_coding | deleterious(0.01) | possibly_damaging(0.511) | TCGA-AR-A2LH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
LEF1 | insertion | Nonsense_Mutation | novel | c.449_450insTGAGTTTGAGAGGGAGGACCAGTCTTGGTCGTGGTGAATTTGAAGT | p.Val151GlufsTer12 | p.V151Efs*12 | Q9UJU2 | protein_coding | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
LEF1 | SNV | Missense_Mutation | rs377048071 | c.706G>A | p.Asp236Asn | p.D236N | Q9UJU2 | protein_coding | tolerated(1) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LEF1 | SNV | Missense_Mutation | novel | c.145G>A | p.Asp49Asn | p.D49N | Q9UJU2 | protein_coding | tolerated(0.05) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LEF1 | SNV | Missense_Mutation | c.826N>A | p.Asp276Asn | p.D276N | Q9UJU2 | protein_coding | tolerated(0.19) | benign(0.009) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
LEF1 | SNV | Missense_Mutation | rs146861754 | c.745G>A | p.Gly249Ser | p.G249S | Q9UJU2 | protein_coding | tolerated(0.45) | benign(0.079) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
LEF1 | SNV | Missense_Mutation | c.362N>G | p.Asn121Ser | p.N121S | Q9UJU2 | protein_coding | tolerated(0.54) | benign(0.017) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LEF1 | SNV | Missense_Mutation | novel | c.788N>C | p.Ile263Thr | p.I263T | Q9UJU2 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LEF1 | SNV | Missense_Mutation | c.914N>T | p.Ala305Val | p.A305V | Q9UJU2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR | |
LEF1 | SNV | Missense_Mutation | novel | c.916N>C | p.Phe306Leu | p.F306L | Q9UJU2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |